| 000 | 02736cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223032256.0 | ||
| 008 | 190506s2018 ua h f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.11.24.M.Sc.2018.Po.O | ||
| 100 | 0 | _aPola Saeed Nasr Soliman | |
| 245 | 1 | 0 |
_aOptical coherence tomography biomarkers for visual outcome after intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection for eyes with diabetic macular edema (DME) / _cPola Saeed Nasr Soliman ; Supervised Amr Abdellatif Osman , Gihan Mohamad Shokier , Rana Ahmed Abdelfattah |
| 246 | 1 | 5 | _aالعلامات البيولوجيه باستخدام جهاز الاشعه المقطعيه التوافقي الضوئي للتنبؤ بحده الابصار بعد حقن مضاد عامل نمو الخلايا المبطنه للاوعيه الدويه داخل الجسم الزجاجي للعيون المصابه بارتشاح المقوله السكري |
| 260 |
_aCairo : _bPola Saeed Nasr Soliman , _c2018 |
||
| 300 |
_a109 P. : _bfacsimiles ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Ophthalmology | ||
| 520 | _aPurpose: To identify Optical coherence tomography (OCT) biomarkers for visual outcome after injection of intraviteal bevacizumab in the treatment of diabetic macular edema (DME). Materials and Methods: Prospective observational study conducted on eyes with DME with central subfield thickness (CST) more than 250 microns. OCT & best corrected visual acuity (BCVA) were done then eyes received three intravitreal injections of bevacizumab then the BCVA and OCT were repeated after one month of the third injection. Results: We found an improvement both functionally and anatomically. Functionally; the pattern of edema especially combined and subretinal fluid can be used as a biomarker for improvement of vision. Anatomically; subretinal fluid can be used as a biomarker for decrease of CST. Conclusions: The pattern of edema could be used as a reliable biomarker for the visual outcome in eyes with DME and the subretinal fluid is another biomarker that could be used to predict both the functional response as well as anatomical improvement of DME after the bevacizumab therapy | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aCST | |
| 653 | 4 | _aDME | |
| 653 | 4 | _aOCT | |
| 700 | 0 |
_aAmr Abdellatif Osman , _eSupervisor |
|
| 700 | 0 |
_aGihan Mohamad Shokier , _eSupervisor |
|
| 700 | 0 |
_aRana Ahmed Abdelfattah , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aAsmaa _eCataloger |
||
| 905 |
_aNazla _eRevisor |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c71827 _d71827 |
||